Exelixis, Inc.

Ancestry.com Dna, LLC

Exelixis Patent Company LLC

Bristol-myers Squibb Compnay

Exelixus, Inc.

Yong Wang

Lynne Canne Bannen

Wei Xu

John M Nuss

Timothy Patrick Forsyth

Morrison B Mac

James William Leahy

Larry Wayne Mann

Jeff Z Chen

Grace Mann

Richard George Khoury

Jason Jevious Parks

Diva Sze-Ming Chan

Tai Phat Huynh

Craig Stacy Takeuchi

Vasu Jammalamadaka

Keith D Noto

Lisa Esther Dalrymple

Wie Xu

Minna Bui

Charles K Marlowe

William Bajjalieh

Faming Jiang

Morrisson B Mac

Sunghoon Ma

Byung Gyu Kim

Catherine Ann Ball

Brian Hugh Ridgway

Kenneth Gregory Chahine

Sergey Epshteyn

Mathew J Barber

Gary Lee Lewis

Joan C Sangalang

Xian Shi

Suleyman Bahceci

Moon Jung Kim

Raju Mohan

Kin Tso

Richard Martin

Tie-Lin Wang

Brenton Todd Flatt

Joerg Bussenius

S David Brown

Patrick C Kearney

Xiao-Hui Gu

Erick Wang Co

Michael Charles Nyman

Amy Lew Tsuhako

Donna Tra Le

Shiya Song

William C Stevens, Jr

Matthew Sangyup Lee

Rhett Ronald Klein

Zerom Tesfai

Jason H Wu

Brett Murphy

William C Stevens

T G Murali Dhar

Neel Kumar Anand

Elena S Koltun

Tsze Tsang

Kenneth D Rice

Jack Maung

Ping Huang

Ross E Curtis

Charles M Blazey

Simona Costanzo

Longcheng Wang

Larisa Dubenko

Chris Allen Buhr

Owen Joseph Bowles

Steven Charles Defina

Tae-Gon Baik

Joon Won Jeong

Katherine Lara

Bryan K S Yeung

Baili Chen

Alisa Elnaz Sedghifar

Andre Everson Kim

Jeff Chen

Maurizio Franzini

Ken Rice

Lynn Canne Bannen

Jeffrey Adrion

Justin Salvant

Benjamin Spangler

Andrew Raub

Natalie Anne Swinford

Ju Zhang

Moon Hwan Kim

Morrison Mac

Chris A Buhr

Patrick Kearney

Larry W Mann

Bryan K S Novartis Institute For Tropical Diseases Yeung

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of protein kinases, and methods for their use in treating disorders mediated, at least in part by, protein kinases.

Pyridone compounds and methods of use

Novel haplotype cluster Markov models are used to phase genomic samples. After the models are built, they rapidly and accurately phase new samples without requiring that the new samples be used to re-build the models. The models set transition probabilities such that the probability for an appearance of any allele within any haplotype is a non-zero number. Furthermore, the most unlikely pairs of haplotypes are discarded from each model at each level until ε of the likelihood mass at each level is discarded. The models are also constructed such that contributing windows of SNPs partially overlap so that phasing decisions near one of the extreme ends of any model is are not significantly determinative of the phase. Additionally, the models are configured such that two or more nodes can be merged during the building/updating procedure to consolidate haplotype clusters having similar distributions.

Haplotype phasing models

A computing device may receive an inheritance dataset of a target named entity. The device may access a plurality of clusters associated with a region, each cluster comprising inheritance data for a plurality of reference panel named entities. The device may determine that the inheritance dataset of the target named entity has at least a threshold amount of inheritance sequences that are classified to the region. The device may compare, for each cluster, the inheritance dataset of the target named entity to the reference panel named entities in the cluster to identify similarities and shared inheritance segments between the target named entity and the reference panel named entities. The device may determine, for each cluster, a metric based on the inheritance segments shared. The device may assign the target named entity to one or more ethnicities based on the comparison between the metric and the threshold specific to the cluster.

Systems and methods for determining ethnicity subregions

Heterocyclic compounds useful as antagonists of adenosine receptors, and methods of treatment of diseases using antagonists of adenosine receptors are disclosed herein. Also disclosed herein are pharmaceutical compositions and methods of administration of heterocyclic antagonists of adenosine receptors and processes for producing heterocyclic antagonists of adenosine receptors.

Heterocyclic adenosine receptor antagonists

Disclosed herein are compounds of Formula (I′). Compounds of Formula (I′) inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

Compounds for the treatment of kinase-dependent disorders

An input sample SNP genotype is divided into a plurality of windows, each including a sequence of SNPs. For each window, a diploid hidden Markov Model (HMM) is built and from a haplotype Markov Model (MM). The diploid HMM for a window is used to determine the probability that the window corresponds to a pair of labels (e.g., ethnicity labels). An inter-window HMM, with a set of states for each window, is built based on the diploid HMMs for each window. Labels are assigned to the input sample genotype based on the inter-window HMM.

Local genetic ethnicity determination system

An input genotype is divided into a plurality of windows, each including a sequence of SNPs. For each window, a diploid HMM is computed based on genotypes and/or phased haplotypes to determine a probability of a haplotype sequence being associated with a particular label. For example, the diploid HMM for a window is used to determine the emission probability that the window corresponds to a set of labels. An inter-window HMM, with a set of states for each window, is computed. Labels are assigned to the input genotype based on the inter-window HMM. Upper and lower bounds are estimated to produce a range of likely percentage values an input can be assigned to a given label. Confidence values are determined indicating a likelihood that an individual inherits DNA from a certain population. Maps are generated with polygons representing regions where a measure of ethnicity of population falls within specific ranges.

Global ancestry determination system

Disclosed herein are compounds of Formula (I'). Compounds of Formula (I&#x2032;) inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

Disclosed herein are compounds of Formula I'. Compounds of Formula I&#x2032; inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. 

Disclosed herein are compounds of formula I. Compounds of formula I inhibit, regulate and/or modulate kinase receptor, particularly Axl and Mer signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds. 

The present invention provides compounds for modulating protein kinase enzymatic activity for modulating cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. More specifically, the invention provides quinazolines and quinolines which inhibit, regulate and/or modulate kinase receptor, particularly c-Met, KDR, c-Kit, flt-3 and flt-4, signal transduction pathways related to the changes in cellular activities as mentioned above, compositions which contain these compounds, and methods of using them to treat kinase-dependent diseases and conditions. The present invention also provides methods for making compounds as mentioned above, and compositions which contain these compounds.

C-met modulators and methods of use

System, computer program products, and methods are disclosed for estimating a degree of ancestral relatedness between two individuals. The haplotype data for a population of individuals is divided into segment windows based on genetic markers, and matched segments for the haplotype data are generated. Each matched segment having a first cM width that exceeds a threshold cM width is included in counting the matched segments in each segment window. A weight associated with each segment window is estimated based on the count of matched segments in the associated segment window. A weighted sum of per-window cM widths for each matched segment is calculated based on the first cM width and the weights associated with the segment windows of the matched segment. The weighted sum of per-window cM widths are used to estimate a degree of ancestral relatedness between two individuals.

Reducing error in predicted genetic relationships

Novel haplotype cluster Markov models are used to phase genomic samples. After the models are built, they rapidly and accurately phase new samples without requiring that the new samples be used to re-build the models. The models set transition probabilities such that the probability for an appearance of any allele within any haplotype is a non-zero number. Furthermore, the most unlikely pairs of haplotypes are discarded from each model at each level until c of the likelihood mass at each level is discarded. The models are also constructed such that contributing windows of SNPs partially overlap so that phasing decisions near one of the extreme ends of any model is are not significantly determinative of the phase. Additionally, the models are configured such that two or more nodes can be merged during the building/updating procedure to consolidate haplotype clusters having similar distributions.

Growing community of inventors

Foster City, CA, United States of America

Yong Wang